Almost-Tight Distributed Minimum Cut Algorithms

We study the problem of computing the minimum cut in a weighted distributed message-passing networks (the CONGEST model). Let $\lambda$ be the minimum cut, $n$ be the number of nodes in the network, and $D$ be the network diameter. Our algorithm can compute $\lambda$ exactly in $O((\sqrt{n} \log^{*} n+D)\lambda^4 \log^2 n)$ time. To the best of our knowledge, this is the first paper that explicitly studies computing the exact minimum cut in the distributed setting. Previously, non-trivial sublinear time algorithms for this problem are known only for unweighted graphs when $\lambda\leq 3$ due to Pritchard and Thurimella's $O(D)$-time and $O(D+n^{1/2}\log^* n)$-time algorithms for computing $2$-edge-connected and $3$-edge-connected components. By using the edge sampling technique of Karger's, we can convert this algorithm into a $(1+\epsilon)$-approximation $O((\sqrt{n}\log^{*} n+D)\epsilon^{-5}\log^3 n)$-time algorithm for any $\epsilon>0$. This improves over the previous $(2+\epsilon)$-approximation $O((\sqrt{n}\log^{*} n+D)\epsilon^{-5}\log^2 n\log\log n)$-time algorithm and $O(\epsilon^{-1})$-approximation $O(D+n^{\frac{1}{2}+\epsilon} \mathrm{poly}\log n)$-time algorithm of Ghaffari and Kuhn. Due to the lower bound of $\Omega(D+n^{1/2}/\log n)$ by Das Sarma et al. which holds for any approximation algorithm, this running time is tight up to a $\mathrm{poly}\log n$ factor. To get the stated running time, we developed an approximation algorithm which combines the ideas of Thorup's algorithm and Matula's contraction algorithm. It saves an $\epsilon^{-9}\log^{7} n$ factor as compared to applying Thorup's tree packing theorem directly. Then, we combine Kutten and Peleg's tree partitioning algorithm and Karger's dynamic programming to achieve an efficient distributed algorithm that finds the minimum cut when we are given a spanning tree that crosses the minimum cut exactly once

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362